Table 2 |
|||
|
Baseline Characteristics of Enrolled Participants (N = 25) |
|||
|
Participant Characteristic |
n |
Mean |
% |
|
|
|||
|
Years of age |
46.4 |
||
|
Male gender |
24 |
96 |
|
|
Race/ethnicity |
|||
|
Caucasian |
17 |
68 |
|
|
African American |
4 |
16 |
|
|
Latino |
4 |
16 |
|
|
Years HIV-infected |
13.7 |
||
|
CD4 cell count |
494/mm3 |
||
|
HIV RNA < 75 copies/mL |
19 |
76 |
|
|
Months on HAART |
82.3 |
||
|
Target dyslipidemia-inducing agents |
|||
|
lopinavir/ritonavir |
15 |
60 |
|
|
atazanavir/ritonavir |
3 |
12 |
|
|
tipranavir/ritonavir |
1 |
4 |
|
|
fosamprenavir/ritonavir |
1 |
4 |
|
|
efavirenz |
5 |
20 |
|
|
Months on target agent |
19.0 |
||
|
History of opportunistic infection |
13 |
52 |
|
|
Cardiac risk factors |
|||
|
Lipodystrophy |
13 |
52 |
|
|
hypertension |
7 |
28 |
|
|
family history of hypertension |
9 |
36 |
|
|
family history of hyperlipidemia |
11 |
44 |
|
|
tobacco smokers |
8 |
32 |
|
|
former smokers |
7 |
28 |
|
|
alcohol users |
15 |
60 |
|
|
former alcohol users |
5 |
20 |
|
|
illicit substance users |
14 |
56 |
|
|
former illicit substance users |
7 |
28 |
|
|
Prior antihyperlipidemic use: |
9 |
36 |
|
|
|
|||
|
Abrams et al. BMC Complementary and Alternative Medicine 2011 11:60 doi:10.1186/1472-6882-11-60 |
|||
